Which of the following medication in the treatment of Parkinson’s disease is an NMDA antagonist?
**Core Concept**
Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra. Medications that modulate the dopaminergic system, such as dopamine agonists and antagonists, are used to manage symptoms. However, in some cases, medications that modulate other neurotransmitter systems, like glutamate, may also be beneficial.
**Why the Correct Answer is Right**
Amantadine is an NMDA antagonist, which means it blocks the action of glutamate at NMDA receptors. Glutamate is an excitatory neurotransmitter that can exacerbate dopaminergic neuron loss and contribute to the progression of Parkinson's disease. By blocking glutamate's action, amantadine may help to slow disease progression and improve motor symptoms.
**Why Each Wrong Option is Incorrect**
**Option A:** Levodopa is a precursor to dopamine and is used to increase dopamine levels in the brain. It does not modulate the glutamate system.
**Option B:** Pramipexole is a dopamine agonist that directly stimulates dopamine receptors, rather than blocking glutamate receptors.
**Option C:** Ropinirole is another dopamine agonist that works similarly to pramipexole, without affecting glutamate receptors.
**Clinical Pearl / High-Yield Fact**
Amantadine also has antiviral properties and was initially developed as a treatment for influenza. However, its use in Parkinson's disease has been largely unrelated to its antiviral effects.
**Correct Answer: C. Ropinirole is incorrect; Amantadine is the correct answer.